Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenfluramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.64 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexfenfluramine SCHEMBL16706 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL16215 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL15669714 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL29499611 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL162006 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL29882976 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL23724055 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL11140094 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL39491 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL30951308 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022207950-A1 | TREATMENT FOR OBESITY | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2022-10-06 | — | — | WO | claimed |
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260139031-A1 | FUSION PROTEIN | LEVICEPT LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4377309-B1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4720104-A1 | LOW AFFINITY P75 NEUROTROPHIC RECEPTOR EXTRACELLULAR DOMAIN FUSED TO A FC MOIETY AS NGF ANTAGONIST THERAPY OF PAIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719596-A1 | FUSION PROTEIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| US-11339202-B2 | Therapeutic use of p75NTR neurotrophin binding protein | LEVICEPT LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-11325902-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-05-10 | — | — | US | disclosed |
| US-20220125743-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-04-28 | — | — | US | disclosed |
| US-20220110923-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-04-14 | — | — | US | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| WO-2022071484-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2022-04-07 | — | — | WO | disclosed |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | SIGMAR1 627/4885HTR2C 823/4885HTR1D 2211/4885 |
| US-20260146036-A1 | CRYSTALLINE FORMS | PRKCD, CCT8, CRYZ | SIGMAR1 124/4885HTR2C 3270/4885HTR1D 1928/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | SIGMAR1 12/4885HTR2C 626/4885HTR1D 184/4885 |
| US-11325902-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SIGMAR1 3234/4885HTR2C 1809/4885HTR1D 1844/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SIGMAR1 3293/4885HTR2C 1892/4885HTR1D 2048/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | SIGMAR1 1065/4885HTR2C 2913/4885HTR1D 3056/4885 |
| US-20220125743-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | HTR2B, HTR1B, CYP4B1 | SIGMAR1 459/4885HTR2C 4/4885HTR1D 67/4885 |
| US-20220110923-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | SCN10A, CACNA1A, SCN3A | SIGMAR1 708/4885HTR2C 1826/4885HTR1D 2561/4885 |
| US-20260139031-A1 | FUSION PROTEIN | NTRK2, BDNF, NGFR | SIGMAR1 843/4885HTR2C 1442/4885HTR1D 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.